Understanding GRHL3: Potential Drug Targets and Biomarkers (G57822)

Target Name: GRHL3

NCBI ID: G57822

GRHL3

Understanding GRHL3: Potential Drug Targets and Biomarkers

Grainyhead (GRHL3) is a protein that is expressed in the brain and nervous system of mammals. It is a member of the G-protein-coupled receptor (GPCR) family and is involved in a wide range of physiological processes in the brain, including neurotransmitter signaling, synaptic plasticity, and mood regulation. Despite its importance, little is known about GRHL3 and its potential as a drug target or biomarker. In this article, we will explore the biology and potential drug targets of GRHL3.

GRHL3 is a 21-kDa protein that is expressed in the brain and nervous system of mammals. It is a member of the GPCR family, which is a large superfamily of transmembrane proteins that are involved in a wide range of physiological processes, including sensory perception, neurotransmitter signaling, and signaling pathways. GPCRs are characterized by a extracellular domain that is involved in protein-protein interactions and a transmembrane domain that is responsible for the protein's unique structure and function.

GRHL3 is involved in a wide range of physiological processes in the brain, including neurotransmitter signaling, synaptic plasticity, and mood regulation. It is a critical regulator of neurotransmitter release from neurons, and is involved in the neurotransmitter systems that are responsible for regulating mood, emotion, and other physiological processes.

GRHL3 is also involved in synaptic plasticity, which is the ability of the brain to change and adapt in response to experience. It is a key regulator of synaptic plasticity, and is involved in the formation of new synapses and the modification of existing ones. This is important for the development and maintenance of neural networks, which are the fundamental structures of the brain and are responsible for a wide range of cognitive processes.

In addition to its role in neurotransmission and synaptic plasticity, GRHL3 is also involved in mood regulation. It is a critical regulator of the brain's reward system, and is involved in the modulation of dopamine release in response to drugs of abuse. It is also involved in the regulation of pain, and is thought to play a role in the development of chronic pain.

GRHL3 is a potential drug target, due to its involvement in a wide range of physiological processes in the brain. Its function as a neurotransmitter regulator makes it an attractive target for small molecules that can modulate neurotransmitter release. In addition, its role in synaptic plasticity and mood regulation makes it an attractive target for drugs that are designed to enhance or modify synaptic plasticity.

In conclusion, GRHL3 is a protein that is expressed in the brain and nervous system of mammals. It is a member of the GPCR family and is involved in a wide range of physiological processes in the brain, including neurotransmission, synaptic plasticity, and mood regulation. Despite its importance, little is known about GRHL3 and its potential as a drug target or biomarker. Further research is needed to fully understand the biology and potential drug targets of GRHL3.

Protein Name: Grainyhead Like Transcription Factor 3

Functions: Transcription factor playing important roles in primary neurulation and in the differentiation of stratified epithelia of both ectodermal and endodermal origin (By similarity). Binds directly to the consensus DNA sequence 5'-AACCGGTT-3' acting as an activator and repressor on distinct target genes (PubMed:21081122, PubMed:25347468). xhibits functional redundancy with GRHL2 in epidermal morphogenetic events and epidermal wound repair (By similarity). Exhibits functional redundancy with GRHL2 in epidermal morphogenetic events and epidermal wound repair but is essential to form the epidermal barrier with TGM3 as critical direct target gene among others. Despite being dispensable during normal epidermal homeostasis in the adulthood, is again required for barrier repair after immune-mediated epidermal damage, regulates distinct gene batteries in embryonic epidermal differentiation and adult epidermal barrier reformation after injury. Plays unique and cooperative roles with GRHL2 in establishing distinct zones of primary neurulation. Essential for spinal closure, functions cooperatively with GRHL2 in closure 2 (forebrain/midbrain boundary) and posterior neuropore closure (By similarity). Also required for proper development of the oral periderm (PubMed:24360809). No genetic interaction with GRHL3, no functional cooperativity due to diverse target gene selectivity (PubMed:21081122)

The "GRHL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GRHL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets